Literature DB >> 11631

Regulation of the cyclic guanosine 3'-5' monophosphate system in human brain tumors.

L Frattola, A Carenzi, C Cerri, K Kumakura, M Trabucchi.   

Abstract

Several reports have suggested that cylcic guanosine 3'-5' monophosphate (cGMP) and cyclic 3'-5' adenosine monophosphate (cAMP) are involved in the regulation of cellular proliferation. Following our previous reports on the cAMP system in human brain tumors, we decided to investigate the cGMP system in the same pathological tissues by studying the activity of guanylate cyclase and cGMP-phosphodiesterase (cGMP-PDE). We found that the activity of both enzymes is lower in neurinomas and glioblastomas than in meningiomas or in normal cerebral cortex. Furthermore, the subcellular distribution of guanylate cyclase in human cerebral cortex differs from that of neurinomas and glioblastomas. On the basis of such observations we have discussed the possibility that the regulatory mechanism of the enzymes related to the cyclic nucleotide metabolism is altered in brain tumors.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 11631     DOI: 10.1111/j.1600-0404.1976.tb04371.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  3 in total

1.  An experimental trial of cyclic nucleotides on multicellular spheroids derived from human brain tumours.

Authors:  N Oktar; J L Darling; D G Thomas
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

2.  Restoring soluble guanylyl cyclase expression and function blocks the aggressive course of glioma.

Authors:  Haifeng Zhu; Jessica Tao Li; Fang Zheng; Emil Martin; Alexander Y Kots; Joshua S Krumenacker; Byung-Kwon Choi; Ian E McCutcheon; Norman Weisbrodt; Oliver Bögler; Ferid Murad; Ka Bian
Journal:  Mol Pharmacol       Date:  2011-09-09       Impact factor: 4.436

3.  Cyclic nucleotides in experimental and human brain tumors.

Authors:  G Racagni; S Pezzotta; M T Giordana; E Iuliano; I Mocchetti; G Spanu; G Sangiovanni; P Paoletti
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.